Omega Flex, Inc. — 2019 Q2 Form 10-Q Summary
Business Context and Reporting Period
Omega Flex manufactures and sells flexible metal hose, corrugated tubing, proprietary fittings and accessories for residential and commercial construction, medical and pharmaceutical, industrial, transportation and other applications. The company operates as one segment, with manufacturing facilities in Pennsylvania and the United Kingdom, and sells primarily through distributors, wholesalers and OEMs.
This unaudited Form 10-Q covers the three and six months ended June 30, 2019, compared with the corresponding 2018 periods. The report was filed August 5, 2019. The company had 10,094,322 shares outstanding at June 30, 2019.
Financial Performance and Position
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Net sales | $26.809 million | $26.847 million | $53.597 million | $52.244 million |
| Gross profit | $16.736 million | $16.214 million | $33.682 million | $31.247 million |
| Gross margin | 62.4% | 60.4% | 62.8% | 59.8% |
| Operating profit | $5.144 million | $6.358 million | $10.735 million | $11.858 million |
| Operating margin | 19.2% | 23.7% | 20.0% | 22.7% |
| Net income attributable to Omega Flex | $3.983 million | $4.776 million | $8.365 million | $8.939 million |
| Basic and diluted EPS | $0.39 | $0.47 | $0.83 | $0.89 |
- Q2 revenue was essentially flat year over year; first-half revenue increased 2.6%.
- Gross profit increased 3.2% in Q2 and 7.8% in the first half, reflecting pricing actions, cost control and operating leverage.
- Operating profit declined 19.1% in Q2 and 9.5% in the first half, primarily because of higher general and administrative expenses.
- Net margin attributable to Omega Flex was approximately 14.9% in Q2 2019 versus 17.8% in Q2 2018, and approximately 15.6% for the first half versus 17.1% in the prior-year period.
- Interest income increased to $236,000 in Q2 and $456,000 for the first half, compared with $94,000 and $145,000, respectively, due to higher invested cash balances.
- Dividends declared were $0.28 per share in Q2 and $0.52 per share for the first half, compared with $0.46 per share for both comparable 2018 periods.
Cash Flow, Liquidity and Debt
- Cash and cash equivalents were $23.920 million at June 30, 2019, down from $32.392 million at December 31, 2018.
- Short-term investments increased to $22.898 million from $14.944 million. Cash used for investment purchases was $22.954 million, partially offset by $15.000 million of investment-sale proceeds.
- Operating cash flow was $5.079 million for the first six months, compared with $6.087 million in 2018.
- Capital expenditures were $722,000, compared with $708,000 in the prior-year period. Spending included projects related to MediTrac products.
- Cash dividends paid were $4.844 million, compared with $4.931 million in the first half of 2018.
- The company had a $15.000 million unsecured revolving credit facility maturing December 1, 2022. There were no borrowings outstanding, and the company was in compliance with all covenants.
- Management stated that existing cash and cash equivalents should be sufficient to meet anticipated cash needs for at least the next twelve months.
- Total assets were $88.215 million and total liabilities were $18.527 million at June 30, 2019. The company recorded $770,000 of right-of-use assets and $789,000 of lease liabilities following adoption of the new lease standard.
Material Changes Versus the Prior Comparable Period
- General and administrative expense increased 37.5% in Q2 and 36.1% for the first half. Legal and product-liability defense costs increased by $1.892 million in Q2 and $2.487 million in the first half, primarily related to a pending class-action case.
- Director compensation increased following the issuance of 2,500 restricted stock units in June 2019.
- Phantom stock compensation expense increased year over year; total phantom-stock liability was $1.892 million at June 30, 2019, compared with $1.692 million at December 31, 2018.
- Engineering expense increased 3.8% in Q2 and 16.5% for the first half, partly reflecting development of MediTrac and DoubleTrac products.
- Inventory increased to $9.387 million from $7.976 million at year-end 2018, while accrued compensation declined to $2.273 million from $5.295 million as prior-year incentive compensation was paid.
- The company adopted ASC Topic 842 on January 1, 2019. The adoption increased operating lease assets and liabilities by approximately $800,000 without a material income statement or cash flow impact.
Outlook, Risks, Contingencies and Unusual Items
The filing does not provide formal quantitative revenue or earnings guidance. Management reported sustained demand and a strong position in its core market, while highlighting expectations for MediTrac and other new product applications. Future capital needs may depend on revenue growth, expansion, acquisitions and capacity investments.
- The company is defending a putative class-action case and other product-liability claims involving potential lightning damage to flexible gas piping products. Management believes the claims lack merit but cannot predict the ultimate outcome.
- Insurance generally covers the claims subject to deductibles or self-insured retentions ranging primarily from $25,000 to $1.000 million per claim. Aggregate maximum exposure for current open claims, excluding the class action, was estimated at approximately $3.2 million as of June 30, 2019.
- Recorded liabilities for legal costs and settlements were $228,000 at June 30, 2019, versus $150,000 at December 31, 2018. The company stated that litigation could materially affect operations, liquidity or insurance costs.
- One customer represented more than 10% of accounts receivable and more than 10% of total sales for the first six months of both 2019 and 2018, creating customer-concentration risk.
- Foreign currency translation reduced other comprehensive income by $55,000 for the first half of 2019. The company had no currency hedging positions.
- The company reported no material subsequent events, no off-balance-sheet arrangements and no additional risk factors attributable to the quarter.
Investor Verification Priorities
- Verify the continued cost, timing and potential exposure associated with the Missouri putative class-action and other product-liability claims.
- Assess whether higher gross margins are sustainable and whether legal, product-liability, director and phantom-stock costs continue to pressure operating margins.
- Monitor revenue growth and customer concentration, particularly the contribution and adoption rate of MediTrac and other newer products.
- Reconcile cash generation with dividend payments, short-term investment activity, inventory growth and future capital expenditures.
- Confirm availability and covenant compliance under the $15.0 million revolving credit facility and the company’s stated twelve-month liquidity outlook.